T-cell-based immunotherapy in colorectal cancer.

Abstract

Colorectal cancer (CRC) is the leading cause of cancer death worldwide. CRC therapeutic strategies include surgical resection, chemotherapy, radiotherapy, and other approaches. However, patients with metastatic CRC have worse prognoses. In recent years, T-cell-based immunotherapy has elicited promising responses in B-cell malignancies, melanoma, and lung cancer, but most CRC patients are resistant to immunotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors have shown encouraging results in non-small cell lung cancer, melanoma, and other cancers, but immune checkpoint blockade is only effective for CRC subset with microsatellite instability. Other immunotherapies, such as cytokines, cancer vaccines, small molecules, oncolytic viruses, and chimeric antigen-receptor therapy, are currently in use against CRC. This review analyzes recent developments in immunotherapy for CRC treatment as well as the challenges in overcoming resistance.

• Authors: Mei Feng, Zhongwei Zhao, Mengxuan Yang, Jiansong Ji, Di Zhu
• Journal: Cancer letters (Cancer Lett) Vol. 498 Pg. 201-209 (02 01 2021) ISSN: 1872-7980 [Electronic] Ireland
• PMID: 33129958 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020. Published by Elsevier B.V.

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Animals
• B-Lymphocytes (drug effects, immunology)
• Colorectal Neoplasms (immunology, therapy)
• Drug Resistance, Neoplasm (immunology)
• Humans
• Immune Checkpoint Inhibitors (pharmacology, therapeutic use)
• Immunotherapy (methods)
• T-Lymphocytes (drug effects, immunology)